TaiMed Biologics
TaiMed Biologics is a Taiwan-based, publicly traded biopharmaceutical company developing monoclonal antibody therapeutics for HIV, commercializing the first FDA-approved mAb for HIV (Trogarzo) and advancing a long-acting dual antibody pipeline through Phase 2b trials.
- Company typePublic
- Founded2007
- HeadquartersTaipei, Taiwan
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What TaiMed Biologics does
TaiMed Biologics (TPEX: 4147) is a Taiwan-based, publicly traded commercial-stage biopharmaceutical company founded in 2007 that develops monoclonal antibody therapeutics for HIV disease. Its flagship commercial product, Trogarzo (ibalizumab), is the world's first and only FDA-approved monoclonal antibody for HIV treatment (approved 2018), acting as a post-attachment inhibitor that binds the CD4 receptor. The company's proprietary technology platform centers on CD4-targeted antibody engineering, including the LM52 glycan modification and histidine modification technologies (patent-protected until 2040) that underpin its second-generation pipeline candidate TMB-365, as well as a first-in-class antibody-drug conjugate (ADC) platform targeting CD4+ T cells. The pipeline lead, TMB-365/TMB-380, is a long-acting dual antibody combination currently in Phase 2b clinical development for first-line HIV maintenance therapy, with FDA Fast Track Designation and peak sales potential estimated up to US$4 billion.
TaiMed operates an asset-light, partnership-driven business model. It generates product revenue through exclusive regional licensing and distribution partners — Theratechnologies (US/Canada), AcedrA (MENA), Wuzhou (Hong Kong/Macau), Orient EuroPharma (Taiwan), Helios (Vietnam), Slim Pharmaceuticals (Sri Lanka), and R-Pharm (Russia) — rather than building its own global salesforce. It also offers contract development and manufacturing (CDMO) services from its cGMP facility in Zhubei, Taiwan (bioreactors 50L-2000L, passed FDA inspections in 2022 and 2023 with zero 483 observations), and signed its first international US CDMO client in October 2024. The company is positioning for global licensing transactions on its TMB-365/380 combination, supported by a NT$1.64 billion capital raise in Q1 2024 and an approved private placement to strategic investors.
Financially, TaiMed reported H1 2024 operating revenue of NT$325.9M (~85% YoY growth) with net cash inflow of NT$76.7M, and H1 2024 cash balance of NT$2.1 billion. The company is led by CEO Dr. Jimmy Chang and was co-founded with David Ho's Aaron Diamond AIDS Research Center; it is included in the MSCI Small Cap Index and recently received Taiwan's 22nd National Innovation Award (2025) for TMB-365/380.
TaiMed Biologics firmographics
Firmographics- Name
- TaiMed Biologics
- Legal name
- 中裕新藥股份有限公司
- Website
- https://taimedbiologics.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- TaiMed Biologics is a Taiwan-based, publicly traded biopharmaceutical company developing monoclonal antibody therapeutics for HIV, commercializing the first FDA-approved mAb for HIV (Trogarzo) and advancing a long-acting dual antibody pipeline through Phase 2b trials.
- Ownership category
- akta.pro rank
TaiMed Biologics industry classification
Industry- Product category
- HIV Therapeutics Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industries
- HIV/AIDS Medicine (HLAKAGAB), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where TaiMed Biologics is headquartered
LocationHeadquarters
- HQ city
- Taipei
- HQ country
- Taiwan
- HQ region
- Asia
Offices2 records
Markets served
TaiMed Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Trogarzo Product Sales: Revenue from global sales of Trogarzo (ibalizumab) through licensing and distribution partnerships in various territories including US, Europe, MENA, Asia regions.
- CDMO Services: Contract development and manufacturing organization services providing cGMP manufacturing, process development, analytical method development and validation, formulation development, and monoclonal antibody stability testing for pharmaceutical clients.
- Licensing and Co-development Agreements: Revenue from licensing TMB-365/380 technology and potential co-development partnerships with global pharmaceutical companies for long-acting HIV therapy.
Go-to-market motion2 records
Distribution channels9 records
Marketing channels4 records
TaiMed Biologics product offering
Product offeringCore offering
TaiMed Biologics develops and commercializes monoclonal antibody therapeutics for HIV disease. Its commercial product Trogarzo (ibalizumab) is the world's first humanized monoclonal antibody approved by the US FDA for the treatment of multidrug-resistant HIV-1 infection. The company is advancing TMB-365/TMB-380, the world's first long-acting dual antibody HIV therapy administered every 8 weeks, and a CD4-targeted ADC platform. It also provides biologics CDMO services from its cGMP facility in Taiwan.
Product overview
TaiMed Biologics is a commercial-stage biopharmaceutical company that has developed and commercialized Trogarzo® (ibalizumab), the world's first and only FDA-approved monoclonal antibody for HIV treatment. The company offers two formulations of Trogarzo: IV Infusion and IV Push. Its pipeline includes TMB-365, a second-generation antibody, TMB-380, a broadly neutralizing antibody, and their combination therapy TMB-365/TMB-380 (currently in Phase 2b), representing the world's first long-acting dual antibody HIV therapy. The company is also developing an innovative Antibody-Drug Conjugate (ADC) platform for HIV treatment. In addition to its proprietary products, TaiMed provides comprehensive CDMO (Contract Development and Manufacturing Organization) services from its cGMP facility in Taiwan.
Differentiator
Problem solved
Functional benefit
Brands
- Trogarzo: First humanized monoclonal antibody (mAb) developed for the treatment of HIV-1 infection, approved by US FDA in 2018
- CDMO Services
Products and services
- Trogarzo (ibalizumab) The world's first humanized monoclonal antibody (mAb) approved for the treatment of HIV-1 infection. Acts as a post-attachment inhibitor by binding to the second extracellular domain of the CD4 receptor, blocking HIV entry while preserving immune function. Indicated for heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection.
- Trogarzo IV Infusion Intravenous infusion formulation of Trogarzo administered every two weeks for the treatment of HIV multi-drug-resistant patients as a last-line therapy.
- Trogarzo IV Push Rapid intravenous push administration option of Trogarzo approved by the FDA for both loading dose (2000mg) and maintenance dose (800mg), offering convenient administration in undiluted form.
- TMB-365 Second-generation Trogarzo monoclonal antibody for HIV treatment and prevention. Exhibits enhanced potency, viral coverage, and half-life. Developed from CD4-targeted antibody technology licensed from Aaron Diamond AIDS Research Center with TaiMed holding exclusive global rights.
- TMB-365/TMB-380 Combination Long-acting dual monoclonal antibody combination for HIV maintenance therapy combining TMB-365 and TMB-380. Administered as a single IV infusion every 8 weeks as a complete regimen. No susceptibility screening required before initiation and zero drug-drug interactions due to antibody-based mechanism not metabolized through liver.
- CD4-Targeted Antibody-Drug Conjugates (ADCs) Precision targeting ADC technology combining monoclonal antibodies with high binding specificity to CD4+ T cells with antiretroviral drug payloads. Triple-action mechanism: serves as carrier for antiretroviral drugs, acts as HIV entry inhibitor, and provides precision antiretroviral activity. First-in-Class ADC platform for HIV treatment.
- Biologics CDMO Services Contract Development and Manufacturing Organization services providing cGMP manufacturing, process development, analytical method development and validation, formulation development, and monoclonal antibody stability testing. Uses single-use technology with bioreactors from 50L to 2000L capacity at the Zhubei facility in Taiwan.
Quantifiable outcome
- 94% of participants maintained HIV-1 RNA below 50 copies/mL at Week 24 in Phase 2a trial
- +4 more outcomes
Companies that use TaiMed Biologics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
TaiMed Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
TaiMed Biologics partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and minor.
- Samsung BiologicscoreSupply agreement for pharmaceutical ingredients for TMB-365, a long-acting biologic candidate currently in development. Collaboration supports continued development and manufacturing needs of TMB-365, following TaiMed's completion of Phase 2b enrollment for TMB-365/380.
- R-PharmminorPost-Approval Named Patient Program supply agreement for Trogarzo in Russia, providing access for patients with limited treatment options.
- National Taiwan University (NTU) School of PharmacyminorMOU for internship and talent development program. 16-week internship program at TaiMed facilities equivalent to 13 academic credits, providing hands-on exposure to biotechnology and biopharmaceutical industries.
- Helios Pharmaceutical Company LimitedcoreStrategic collaboration for commercialization of Trogarzo in Vietnam. Leading pharmaceutical local distributor committed to advancing patient access to innovative medicines and aligning Vietnam's healthcare system with global standards.
- Marigold TherapeuticsminorStrategic investment in Marigold Therapeutics to advance ADC drug development. Marigold has core ADC technology platform with founding team experienced in ADC molecule development. Headquartered in Cayman Islands with R&D team being built in Taiwan.
- Slim Pharmaceuticals (Pvt) LtdcoreExclusive license agreement for Trogarzo in Sri Lanka. Leading distributor of high-quality pharmaceuticals established in 2011, headquartered in Sri Lanka.
- US-based Biotechnology ClientcoreFirst international CDMO contract from US client for manufacturing antibody drug for clinical trials. Demonstrates international recognition of TaiMed's CDMO service capabilities.
- Orient EuroPharma Company Limited (OEP)coreExclusive license agreement for Trogarzo commercialization in Taiwan. OEP pursues regulatory approval and commercial sales. Established in 1982, listed on Taiwan GreTai Securities Market (stock code: 4120), with global workforce exceeding 1,000 employees.
- Wuzhou Drug International Trading Co., Ltd.coreExclusive license agreement for Trogarzo in Hong Kong and Macau. Macau pharmaceutical company that has introduced more than ten blockbuster products into China within five years. BLA submitted to regulatory authorities.
- AcedrA BioPharmaceuticalscoreExclusive license, commercialization and distribution agreement for Trogarzo in Middle East and North Africa region (Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Jordan, Egypt, Lebanon, Iraq, Libya, Tunisia, Algeria, Morocco, Sudan). Saudi-based company focused on orphan drugs and niche therapeutic segments.
- WEP Clinical Ltd.minorNamed Patient Program (NPP) collaboration for Trogarzo in Europe and regions beyond US and Canada. Professional services company helping patients obtain medications when no other treatment options are available.
- Theratechnologies Inc.coreExclusive marketing partner for Trogarzo in United States and Canada. Partnership continues despite announcement of Future Pak acquisition of Theratechnologies expected to close Q4 2025.
- Aaron Diamond AIDS Research Center (ADARC)coreTechnology licensing for CD4-targeted antibody technology platform used in TMB-365 development. Led by Dr. David Ho.
- National Institutes of Health (NIH)coreNon-exclusive licensing agreement from NIAID for TMB-380 (VRC07-523LS), a broadly neutralizing HIV-1 antibody. NIH conducted successful Phase 1 trial demonstrating efficacy in HIV patients receiving bi-monthly IV infusion.
- The Rockefeller UniversityminorResearch partnership for HIV antibody development and technology advancement.
- Tanvex BioPharma IncminorCollaboration with biotech and medical institutions for research and development of technologies promoting human well-being.
Scale indicators14 records
Recent moves8 records
Expansion highlights6 records
TaiMed Biologics competitors and assessment
Company assessmentDirect peers
- ViiV Healthcare: Majority-owned by GSK, ViiV is the leading global HIV-focused pharmaceutical company with long-acting injectables like Cabenuva (cabotegravir/rilpivirine) and Apretude. It is the most direct competitor to TaiMed's TMB-365/380 in the long-acting HIV maintenance therapy space.
- Theratechnologies: Exclusive marketing partner for Trogarzo in US/Canada. Theratechnologies is a specialty HIV-focused company developing Trogarzo and other HIV therapeutics, with deep domain overlap though it functions as a commercial rather than R&D peer for TaiMed.
Emerging players
- CytoDyn: Clinical-stage biotech developing leronlimab, a CCR5-targeting mAb, for HIV and other indications. CytoDyn is an emerging mAb-focused HIV therapeutic developer with comparable niche positioning, though with different mechanism and clinical profile.
Broad incumbents
- AbbVie: Diversified biopharmaceutical company with a strong immunology and infectious disease portfolio. AbbVie's expertise in mAb development and commercialization (Humira, Skyrizi) makes it a relevant peer and potential acquirer for TaiMed's mAb platform.
- Gilead Sciences: Largest HIV franchise globally with Biktarvy, Descovy, and the recently approved long-acting capsid inhibitor lenacapavir (Sunlenca). Gilead is both a competitor in long-acting HIV and a potential acquirer/licensor for TaiMed's TMB-365/380 platform.
- Merck & Co. Major HIV therapy player with doravirine (Pifeltro) and ongoing development of once-monthly oral islatravir combinations. Merck's combination therapies compete in the same maintenance therapy market TaiMed targets with TMB-365/380.
- Lonza Group: Largest global CDMO with extensive biologics manufacturing capabilities. Lonza is a relevant peer for TaiMed's growing CDMO business, providing scale benchmarks in cGMP contract manufacturing for monoclonal antibodies.
- WuXi Biologics: Leading global biologics CDMO providing end-to-end mAb development and manufacturing services. WuXi is a direct competitor for TaiMed's CDMO service business and shares exposure to mAb manufacturing scale-up.
- Regeneron Pharmaceuticals: Leading mAb development platform (VelocImmune) with deep expertise in antibody engineering, similar to TaiMed's proprietary antibody engineering capabilities (LM52 glycan, histidine modification). Relevant as a technology platform peer.
Others
- Samsung Biologics: Global CDMO partner for TaiMed's TMB-365 supply. Samsung Biologics is one of the world's largest contract manufacturers and a relevant peer in the CDMO services space where TaiMed increasingly competes.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
TaiMed Biologics social profiles
Digital presenceTaiMed Biologics compliance and trust
Trust signalCompliance3 records
TaiMed Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
TaiMed Biologics leadership team
Management profileNumber of profiles
Profiles6 records
TaiMed Biologics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TaiMed Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TaiMed Biologics
What does TaiMed Biologics do?
TaiMed Biologics develops and commercializes monoclonal antibody therapeutics for HIV disease. Its commercial product Trogarzo (ibalizumab) is the world's first humanized monoclonal antibody approved by the US FDA for the treatment of multidrug-resistant HIV-1 infection. The company is advancing TMB-365/TMB-380, the world's first long-acting dual antibody HIV therapy administered every 8 weeks, and a CD4-targeted ADC platform. It also provides biologics CDMO services from its cGMP facility in Taiwan.
Is TaiMed Biologics a public or private company?
TaiMed Biologics is a public company. It is classified as public and is currently operating.
When was TaiMed Biologics founded?
TaiMed Biologics was founded in 2007. It employs 51 to 100 people.
Where is TaiMed Biologics based?
TaiMed Biologics is headquartered in Taipei, Taiwan, in the Asia region.
How does TaiMed Biologics make money?
Three revenue lines are on record. Trogarzo Product Sales are the primary driver. The others are CDMO Services and licensing and Co-development Agreements.
Who are TaiMed Biologics's main competitors?
Direct peers on record are ViiV Healthcare and Theratechnologies. CytoDyn is listed as an emerging player. Broad incumbents are AbbVie, Gilead Sciences, Merck & Co., Lonza Group, WuXi Biologics and Regeneron Pharmaceuticals. Samsung Biologics is listed as an others.
Does TaiMed Biologics have an API?
No public API is recorded for TaiMed Biologics.
What industry is TaiMed Biologics in?
TaiMed Biologics's product category is HIV Therapeutics Biologics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAKAGAB, HIV/AIDS Medicine. Its NAICS code is 325414 and its SIC code is 2836.